Drug Interactions between pegulicianine and Urogesic Blue
This report displays the potential drug interactions for the following 2 drugs:
- pegulicianine
- Urogesic Blue (hyoscyamine/methenamine/methylene blue/sodium biphosphate)
Interactions between your drugs
methylene blue pegulicianine
Applies to: Urogesic Blue (hyoscyamine / methenamine / methylene blue / sodium biphosphate) and pegulicianine
GENERALLY AVOID: Coadministration with blue and possibly other dyes used for sentinel lymph node (SLN) mapping procedures may reduce the efficacy of pegulicianine imaging. The proposed mechanism is interference with the fluorescent signal from pegulicianine by the dye. Blue dyes have been demonstrated to fluoresce at the same wavelengths as the active metabolites of pegulicianine, which may reduce its capacity to produce the fluorescent signal that is used to differentiate cancerous tissue from normal cells. Concomitant use of any dye for SLN mapping on the day of surgery prior to imaging the lumpectomy cavity was listed in the exclusion criteria in clinical trials evaluating pegulicianine; hence, clinical data are not available.
MANAGEMENT: Administration of dyes for sentinel lymph node (SLN) mapping procedures should generally be avoided prior to imaging the lumpectomy cavity in patients receiving pegulicianine.
References (5)
- (2024) "Product Information. Lumisight (pegulicianine)." Lumicell, Inc.
- Pellini F, Bertoldi L, deguidi g, et al. (2022) "The use of indocyanine green as the only tracer for the identification of the sentinel lymph node in breast cancer: safety and feasibility." Gland Surg, 11, p. 1139-47
- Nagao T, Kinoshita T, Hojo T, Kurihara H, tsuda h (2012) "Sentinel lymph node biopsy using indigo carmine blue dye and the validity of '10% rule' and '4 nodes rule.'" Breast, 21, P455-8
- Lumicell, Inc. (2024) Investigation of novel surgical imaging for tumor excision (INSITE). https://clinicaltrials.gov/study/NCT03686215
- Smith BL, hunt kk, Carr D, et al. (2024) Intraoperative fluorescence guidance for breast cancer lumpectomy surgery. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200333#ap1
Drug and food interactions
sodium biphosphate food
Applies to: Urogesic Blue (hyoscyamine / methenamine / methylene blue / sodium biphosphate)
ADJUST DOSING INTERVAL: Bowel cleansing products can increase the gastrointestinal transit rate. Oral medications administered within one hour of the start of administration of the bowel cleansing solution may be flushed from the gastrointestinal tract and not properly absorbed.
MANAGEMENT: Patients should be advised that absorption of oral medications may be impaired during bowel cleansing treatment. Oral medications (e.g., anticonvulsants, oral contraceptives, antidiabetic agents, antibiotics) should not be administered during and within one hour of starting bowel cleansing treatment whenever possible. However, if concomitant use cannot be avoided, monitoring for reduced therapeutic effects may be advisable.
References (2)
- "Product Information. Golytely (polyethylene glycol 3350 with electrolytes)." Braintree
- (2022) "Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate)." Ferring Pharmaceuticals Inc
hyoscyamine food
Applies to: Urogesic Blue (hyoscyamine / methenamine / methylene blue / sodium biphosphate)
GENERALLY AVOID: Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous. In addition, the potential for abuse may be increased with the combination. The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system. No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load. However, one study found impairment of attention in subjects given atropine 0.5 mg or glycopyrrolate 1 mg in combination with alcohol.
MANAGEMENT: Alcohol should generally be avoided during therapy with anticholinergic agents. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.
References (1)
- Linnoila M (1973) "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol, 6, p. 107-12
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.